Summary
This 2022 Nature Biomedical Engineering review examines the analytical landscape of cell-free DNA technologies for cancer detection and diagnosis. The authors synthesise understanding of current technological capabilities and constraints that limit routine clinical adoption, whilst identifying emerging opportunities to enhance diagnostic performance. The paper addresses the gap between the theoretical promise of cfDNA-based approaches and practical limitations in oncological practice.
Regional applicability
UK oncology services and diagnostics laboratories would benefit from awareness of cfDNA technology maturity and implementation barriers outlined here, informing adoption decisions and research investment priorities. The findings are relevant to NHS stratified medicine initiatives and clinical laboratory standard-setting.
Key measures
Analytical sensitivities and specificities of cfDNA detection methods; clinical limitations and technical constraints; diagnostic performance metrics as suggested by review scope
Outcomes reported
The paper synthesises current understanding of cell-free DNA (cfDNA) analytical capabilities, technological barriers to clinical adoption, and emerging opportunities to improve diagnostic performance in oncology.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.